Key Highlights For Patient Education Surrounding FGFR Inhibitors

EP: 1.Intrahepatic Cholangiocarcinoma Overview

EP: 2.Risk Factors Leading to Various Liver Cancers

EP: 3.Clinical Presentations of Patients With Cholangiocarcinoma

EP: 4.The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

EP: 5.First- and Second-Line Treatment Options for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Alterations

EP: 6.Next-Gen Inhibitors Shaping Cholangiocarcinoma Treatment Landscape

Now Viewing

EP: 7.Key Highlights For Patient Education Surrounding FGFR Inhibitors

EP: 8.Common Adverse Events Associated With FGFRi Therapy

EP: 9.Patient Perspective Regarding FGFRi Adverse Event Profiles

EP: 10.Symptoms Associated With Eye-Related Toxicities Amid FGFRi Therapy

EP: 11.Monitoring and Managing Hyperphosphatemia

EP: 12.Navigating FGFRi Therapy Adverse Effects: Nail Toxicities

EP: 13.FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

EP: 14.Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

This is a video synopsis/summary of a OncLive Insights involving: Lipika Goyal, MD; Chaundra Bishop; R. Katie Kelley, MD; and Caroline Kuhlman, NP.

Kuhlman explained that because oral FGFR inhibitors seem convenient, patients may underestimate potential adverse effects compared to intravenous chemotherapy. However, toxicities covering multiple body systems can be mild to severe, significantly impacting quality of life. Patients need understanding of what to realistically expect regarding safety and tolerability.

Kuhlman covers possible adverse effects like ocular issues, mucositis, alopecia, electrolyte changes, and hyperphosphatemia. She emphasizes sharing symptom specifics, as in what is normal vs concerning and requires prompt reporting.

She concludes that unlike intermittent chemotherapy, daily oral therapy provides no symptom breaks. Optimal preparation and early adverse effect intervention are key. Patients need full counseling on expectations, vigilance, and reporting to enable rapid support.

In summary, while convenient, oral FGFR inhibitors warrant thorough pretreatment counseling as some patients underestimate potential adverse impacts. Patients require education on adverse effects and prompt reporting for early mitigation.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.